Adlai Nortye ANL
NASDAQ ANL
$15.01 +0.26 (+1.76%)
At close: Sep 4, 2026 · 4:00 PM EDT

Adlai Nortye (ANL) Non-Current Assets (2022 - 2026)

Adlai Nortye (ANL) posted quarterly Non-Current Assets of $7.5 million for Q4 2025, up 4.65% year-over-year from $7.2 million in Q4 2024, and up 14.81% quarter-over-quarter from $6.6 million in Q2 2025.

Analysis

Adlai Nortye (ANL) Non-Current Assets (2022 - 2026) Analysis & Trends

Adlai Nortye (ANL) has reported Non-Current Assets for 4 consecutive years, with $7.5 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Non-Current Assets rose 4.65% year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $28.7 million (down 42.44% YoY), while the FY2025 annual figure was $7.5 million, up 4.65% from the prior year.
  • Non-Current Assets improved to $7.5 million in Q4 2025 per ANL's latest filing, from $6.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $29.0 million in Q4 2023 and bottomed at $6.3 million in Q4 2022.
  • Historically, Non-Current Assets has averaged $10.7 million across 4 years, with a median of $7.3 million in 2024.
  • Annual changes were most pronounced in 2023 — Non-Current Assets soared 360.88% — and 2024, when it slumped 75.15%.
  • Adlai Nortye's Non-Current Assets stood at $6.3 million in 2022, then jumped by 360.88% to $29.0 million in 2023, then plunged by 75.15% to $7.2 million in 2024, then gained by 4.65% to $7.5 million in 2025.
  • Business Quant data shows ANL's Non-Current Assets at $7.5 million in Q4 2025, $6.6 million in Q2 2025, and $7.2 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 14.88 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 23.28 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.15 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 294.93 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.96 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 938.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 18.06 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 468.65 Mn
10 Adlai Nortye 500.08 Mn 268.19 Mn - 7.48 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.48 Mn
Dec 31, 2025 7.54 Mn
Jun 30, 2025 6.57 Mn
Dec 31, 2024 7.21 Mn
Jun 30, 2024 7.40 Mn
Dec 31, 2023 28.99 Mn
Dec 31, 2022 6.29 Mn